Folate, Vitamin B12 Tied to GDM Risk in Early Pregnancy
|
By LabMedica International staff writers Posted on 12 Oct 2021 |

Image: The SCIEX QTRAP 6500+ system combines triple quadrupole mass spectrometry with linear ion trap (LIT) (Photo courtesy of Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences)
Gestational diabetes mellitus (GDM) is a common medical disorder in pregnancy, estimated to affect more than 20 million pregnancies worldwide, and causes significant short- and long-term consequences to both the women and their offspring.
Folate and B12 are essential micronutrients for the metabolism of single carbon atoms (known as 1-C metabolism) and these pathways are involved in DNA methylation and synthesis of amino acids, nucleic acids and lipids. Low vitamin B12 and low/high folate levels may contribute to GDM risk, but there is conflicting evidence.
Health Scientist at the Warwick Medical School (Coventry, UK) carried out a prospective, multi-center, multi-ethnic cohort study of 4,746 participants who were pregnant women aged between 18 and 45 years who were at less than 16 weeks of gestation. A random blood sample at booking and fasting and two hour blood samples at Oral Glucose Tolerance Test (OGTT) using 75 grams of anhydrous glucose after an overnight fast of at least 10 hours were taken.
Plasma glucose was determined by the hexokinase enzymatic method using a Synchron CX7 auto-analyzer (Beckman Coulter, Fullerton, CA, USA). Serum B12 and folate were measured by electro-chemiluminescent immunoassay (Roche Cobas analyzer, Roche Diagnostics, Burgess Hill, UK). Plasma total homocysteine (tHcy) was determined by stable isotopic dilution analysis using a Shimadzu HPLC system (Milton Keynes, UK) with an auto-sampler coupled to the detection system of an AB Sciex 6500 QTrap tandem mass spectrometer (liquid chromatography mass spectrometry [LCMS]) (Applied Biosystems, Warrington, UK).
The investigators reported that GDM prevalence was between 12.5% and 14.7%. Folate deficiency (1.3%) was rare but B12 insufficiency (42.3% at <220 pmol/L) and folate excess (36.5%) were common in early pregnancy. Early pregnancy median B12 levels were lower and folate levels higher, in women who were diagnosed with GDM at 26–28 weeks and B12 was negatively associated with fasting plasma glucose. Total homocysteine was inversely associated with blood glucose level and risk of GDM. The associations strengthened when adjusted for BMI, suggesting that the total homocysteine effect on blood glucose level/GDM is independent of BMI, B12 and folate.
The authors concluded that B12 insufficiency and folate excess were common in early pregnancy. Low B12 and high folate levels in early pregnancy were associated with small but statistically significant changes in maternal blood glucose level and higher relative risk (RR) of GDM. The findings warrant additional studies on the role of unmetabolized folic acid in glucose metabolism and investigating the effect of optimizing early pregnancy or pre-conception B12 and folate levels on subsequent hyperglycemia. The study was originally published on July 22, 2021 in the journal Diabetologia.
Related Links:
Warwick Medical School
Beckman Coulter
Roche Diagnostics
Shimadzu
Applied Biosystems
Folate and B12 are essential micronutrients for the metabolism of single carbon atoms (known as 1-C metabolism) and these pathways are involved in DNA methylation and synthesis of amino acids, nucleic acids and lipids. Low vitamin B12 and low/high folate levels may contribute to GDM risk, but there is conflicting evidence.
Health Scientist at the Warwick Medical School (Coventry, UK) carried out a prospective, multi-center, multi-ethnic cohort study of 4,746 participants who were pregnant women aged between 18 and 45 years who were at less than 16 weeks of gestation. A random blood sample at booking and fasting and two hour blood samples at Oral Glucose Tolerance Test (OGTT) using 75 grams of anhydrous glucose after an overnight fast of at least 10 hours were taken.
Plasma glucose was determined by the hexokinase enzymatic method using a Synchron CX7 auto-analyzer (Beckman Coulter, Fullerton, CA, USA). Serum B12 and folate were measured by electro-chemiluminescent immunoassay (Roche Cobas analyzer, Roche Diagnostics, Burgess Hill, UK). Plasma total homocysteine (tHcy) was determined by stable isotopic dilution analysis using a Shimadzu HPLC system (Milton Keynes, UK) with an auto-sampler coupled to the detection system of an AB Sciex 6500 QTrap tandem mass spectrometer (liquid chromatography mass spectrometry [LCMS]) (Applied Biosystems, Warrington, UK).
The investigators reported that GDM prevalence was between 12.5% and 14.7%. Folate deficiency (1.3%) was rare but B12 insufficiency (42.3% at <220 pmol/L) and folate excess (36.5%) were common in early pregnancy. Early pregnancy median B12 levels were lower and folate levels higher, in women who were diagnosed with GDM at 26–28 weeks and B12 was negatively associated with fasting plasma glucose. Total homocysteine was inversely associated with blood glucose level and risk of GDM. The associations strengthened when adjusted for BMI, suggesting that the total homocysteine effect on blood glucose level/GDM is independent of BMI, B12 and folate.
The authors concluded that B12 insufficiency and folate excess were common in early pregnancy. Low B12 and high folate levels in early pregnancy were associated with small but statistically significant changes in maternal blood glucose level and higher relative risk (RR) of GDM. The findings warrant additional studies on the role of unmetabolized folic acid in glucose metabolism and investigating the effect of optimizing early pregnancy or pre-conception B12 and folate levels on subsequent hyperglycemia. The study was originally published on July 22, 2021 in the journal Diabetologia.
Related Links:
Warwick Medical School
Beckman Coulter
Roche Diagnostics
Shimadzu
Applied Biosystems
Latest Clinical Chem. News
- New Chairside Oral Swab Test Could Guide Biopsy Decisions in Oral Cancer
- Multi-Protein Blood Test Improves Staging of Alzheimer’s Disease
- Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
- AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer
- Compact Prenatal Screening System Expands Access to Preeclampsia Testing
- Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
- Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
- Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
- Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
- Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
- Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
Channels
Molecular Diagnostics
view channel
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read morePathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







